Jonathan C. Javitt
Chairman and Chief Scientist · NRX Pharmaceuticals, Inc.
IndividualBuying only
- 2024
- Apr 9, 2025
- 2
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Jonathan C. Javitt's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- RA CAPITAL MANAGEMENT, L.P. - $430.69M in PBLS purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Paul R. Vigano - $371.84M in AVAH purchases and sales in the last 12 months
- Robert M. Williams Jr. - $371.84M in AVAH purchases and sales in the last 12 months
- August J. Troendle - $358.45M in MEDP purchases and sales in the last 12 months
- J.H. Whitney Equity Partners VII, LLC - $319.15M in AVAH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jonathan C. Javitt?
Jonathan C. Javitt is a corporate insider, tracked as Chairman and Chief Scientist of NRX Pharmaceuticals, Inc. (NRXP). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Jonathan C. Javitt last file a Form 4?
The most recent primary Form 4 on record is dated 9 April 2025, one of 2 filings going back to 2024.
Has Jonathan C. Javitt been buying or selling stock?
Recorded transactions: 1 open-market purchase ($47K) and 0 open-market sales across all tracked filings.
